Eurocine Vaccines AB (publ) reported earnings results for the third quarter and nine months ended March 31, 2023. For the third quarter, the company reported revenue was SEK 0.002 million. Net loss was SEK 3.21 million compared to SEK 5.64 million a year ago. Basic loss per share from continuing operations was SEK 0.115 compared to SEK 0.397 a year ago. Diluted loss per share from continuing operations was SEK 0.115 compared to SEK 0.397 a year ago.
For the nine months, revenue was SEK 0.005 million. Net loss was SEK 15.26 million compared to SEK 14.96 million a year ago.